Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
Holding LUNG?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.44Last Year’s EPS
-$0.36Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -9.43%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth, successful expansion initiatives, and positive clinical trial results. However, challenges such as operating losses, seasonal impacts, and conservative guidance were noted. The strategic initiatives and cash position provide a strong base for future growth.Company Guidance
During the Pulmonx Third Quarter 2024 earnings call, the company provided guidance for full-year revenue, gross margin, and operating expenses. They reiterated their revenue guidance for 2024, projecting a range of $81 million to $84 million, representing approximately 20% growth at the midpoint. Gross margins are expected to be around 74%, influenced slightly by the strength of distributor revenue. Operating expenses are forecasted to fall between $122 million and $124 million, with approximately $22 million attributed to non-cash stock-based compensation. The company also reported achieving worldwide sales of $20.4 million for Q3, which reflects a 15% growth over the same period last year. U.S. revenue saw a 17% year-over-year increase, reaching $13.8 million, while international revenue grew by 12% to $6.6 million. Pulmonx's strategic focus remains on expanding market opportunities through their Zephyr Valve treatment and the development of their LungTraX Platform.Revenue Growth
Worldwide sales reached $20.4 million, representing a 15% growth over the same period of the prior year. U.S. revenue grew by 17%, while OUS revenue grew by 12% year-over-year.
Expansion and New Accounts
15 new accounts were added in the U.S. in Q3, ending the quarter with 280 active accounts. This reflects the success of the strategy to train physicians and establish high-performing centers.
Innovative LungTraX Platform
LungTraX Platform is in pilot release, designed to streamline customer workflows and identify eligible patients for Zephyr Valves. It is receiving high interest from customers.
Positive Clinical Data
The AeriSeal CONVERT 1 trial showed successful conversion of collateral ventilation status in 77.6% of patients. Zephyr Valves showed long-term safety and durability benefits.
Strong Cash Position
The company ended the quarter with $107.8 million in cash, cash equivalents, and marketable securities, providing confidence in reaching cash flow breakeven.
---
LUNG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LUNG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $6.79 | $6.25 | -7.95% |
| Jul 31, 2024 | $6.91 | $6.49 | -6.08% |
| May 01, 2024 | $7.72 | $9.38 | +21.50% |
| Feb 21, 2024 | $14.50 | $11.86 | -18.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pulmonx (LUNG) report earnings?
Pulmonx (LUNG) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Pulmonx (LUNG) earnings time?
Pulmonx (LUNG) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LUNG EPS forecast?
LUNG EPS forecast for the fiscal quarter 2024 (Q4) is -$0.44.
---